HemoShear, LLC Announces Issuance of New U.S. Patent For its Human Cell-Based Surrogate Systems

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled “Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease.” This patent covers HemoShear’s core technology which replicates the biology of healthy and diseased human organ systems by applying physiologically-relevant hemodynamic (blood flow) forces and other conditions to organ-specific primary cells.

Back to news